VX 407
Alternative Names: VX-407Latest Information Update: 26 Jun 2024
Price :
$50 *
At a glance
- Originator Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autosomal dominant polycystic kidney disease
Most Recent Events
- 17 Apr 2024 Phase-I clinical trials in Autosomal dominant polycystic kidney disease (In volunteers) in USA (PO) (NCT06345755)
- 21 Mar 2024 US FDA approves IND Application for VX 407 in Autosomal dominant polycystic kidney disease
- 07 Jan 2024 Vertex pharmaceuticals plans a phase I trial for Autosomal dominant polycystic kidney disease (In volunteers) (unspecified route) in March 2024